대한약품

023910KOSDAQ의약품 제조업

60.5 / 100

Reference Date: 2026-04-13

Financial Score32.0 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Slightly down 3.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Daehan Pharmaceuticals primarily produces and sells essential pharmaceuticals such as intravenous solutions, ampoules, and OTC products like lens cleaning solutions. In 2024, the company achieved revenue of 204.1 billion won and operating profit of 38 billion won. Through investments in new production lines and automated warehouses, the company has enhanced its large-scale manufacturing and quality control capabilities, maintaining over 80% of sales in hospitals and pharmacies domestically.

Number of Employees

737people

Average Salary

61.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

6.08Industry Average 14.808.0Point

Half of industry avg (excellent)

PBR

0.57Industry Average 1.045.5Point

Lower than industry avg (good)

ROE

9.60Industry Average 4.427.0Point

2.2x industry avg (excellent)

Debt Ratio

1.31Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.2% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼5.9% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 11.5% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (37%)

Current 28,600Won52-week high 33,70052-week low 25,550

1-month return2.0Point

1m -3.05% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral정기주주총회결과2026-03-26
Neutral감사보고서제출2026-03-18
Neutral사업보고서 (2025.12)2026-03-18